Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pardoprunox Safety Extension in Early PD
NCT00332917Phase 3Completed
- Sponsor
- Solvay
- Start
- Feb 2007
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, open-label, single-arm trial of pardoprunox in Parkinson's disease (PD), sponsored by Solvay. Primary endpoint: Safety (laboratory data, adverse events, vital signs, ECG) at 24 weeks. Started Feb 2007; status: completed.
02
Drugs
pardoprunox
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00332917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00332917.